O

Oruka Therapeutics

Clinical-stage antibody therapies for psoriasis

Associate Director - Multiple Teams

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • Experience with monoclonal antibodies, including both monotherapy and co-formulation, is required.
  • Experience with prefilled syringe and autoinjector selection studies is required.
  • A Master's degree with at least 8 years of relevant experience, or a PhD with at least 6 years of relevant experience, in a scientific discipline and formulation development and/or drug product development is required.
  • Relevant industry experience in phase-appropriate formulation development and container closure selection studies is required.
  • Experience with methods including ultrahigh-performance or high-performance liquid chromatography, capillary electrophoresis, spectrophotometry, bioassays (ELISA and cell-based), and device functional testing is required.
  • Experience with formulation robustness studies supporting process characterization, process performance qualification, and commercialization is required.
  • Experience with late-phase comparability studies, especially those geared toward commercialization, is required.
  • Experience authoring or contributing to regulatory filings, specifically Module 3 documentation for formulation development and stability studies, is required.
  • A demonstrated track record of successful technology transfers between contract development and manufacturing organizations, with a focus on late-stage development and commercial launch, is required.
  • Strong writing, organization, communication, and people-management skills are required, as is the ability to work effectively with diverse internal and external stakeholders.
  • A creative and strategic mindset and the ability to work in a fast-paced environment are required.

Responsibilities

  • Lead phase-appropriate biologics formulation development workflows, including selection, optimization, and robustness studies, with a focus on high-concentration product development.
  • Develop co-formulation products.
  • Conduct prefilled syringe and autoinjector selection and testing.
  • Partner with drug product and clinical teams to select container closures aligned with the target product profile and clinical needs.
  • Design and execute in-use compatibility studies supporting subcutaneous administration of high-concentration biologics.
  • Partner with analytical development to verify that assays are not affected by formulation changes.
  • Drive formulation strategies for robustness and comparability studies, regulatory submissions, and post-approval changes.
  • Partner with process development, manufacturing, quality, and regulatory teams to support late-stage development, technology transfer, and commercial launch readiness.
  • Support formulation risk assessments, control strategy development, and lifecycle management activities.
  • Serve as formulation lead for regulatory interactions, including agency questions and inspections.
  • Build, mentor, and lead a high-performing formulation development team, internally and/or externally.
  • Set technical direction, priorities, and timelines for late-stage formulation deliverables.
  • Manage and provide technical oversight to contract development and manufacturing organizations and contract laboratories.
  • Review and approve formulation development protocols, development reports, and regulatory documentation.

Desired Qualifications

  • Experience supporting drug product process development studies is a plus.

About the Company

Oruka Therapeutics

Clinical-stage antibody therapies for psoriasis

Oruka Therapeutics develops antibody-based therapies for chronic skin diseases, focusing on plaque psoriasis and psoriatic arthritis. Its monoclonal antibodies, discovered and engineered by Paragon Therapeutics, are designed for longer dosing intervals to improve patient convenience. ORKA-001 targets IL-23p19 with an extended half-life that could allow dosing once or twice a year, while ORKA-002 targets IL-17A/F with dosing two to three times per year; both are in early-stage trials with Phase 2 planned for 2025–2026. The company aims to deliver higher skin clearance and durable remission to the large patient pool, pursuing commercialization after advancing through clinical trials; it entered public markets via a 2024 reverse merger with ARCA biopharma and raised over $475 million to fund operations through 2027.

Company size
11-50
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Oruka Therapeutics

See more jobs